These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 16371039)
1. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Snyder E; McCullough J; Slichter SJ; Strauss RG; Lopez-Plaza I; Lin JS; Corash L; Conlan MG; Transfusion; 2005 Dec; 45(12):1864-75. PubMed ID: 16371039 [TBL] [Abstract][Full Text] [Related]
2. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Murphy S; Snyder E; Cable R; Slichter SJ; Strauss RG; McCullough J; Lin JS; Corash L; Conlan MG; Transfusion; 2006 Jan; 46(1):24-33. PubMed ID: 16398727 [TBL] [Abstract][Full Text] [Related]
3. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial. Pineda A; McCullough J; Benjamin RJ; Cable R; Strauss RG; Burgstaler E; Porter S; Lin L; Metzel P; Conlan MG; Transfusion; 2006 Apr; 46(4):562-71. PubMed ID: 16584432 [TBL] [Abstract][Full Text] [Related]
4. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Janetzko K; Cazenave JP; Klüter H; Kientz D; Michel M; Beris P; Lioure B; Hastka J; Marblie S; Mayaudon V; Lin L; Lin JS; Conlan MG; Flament J Transfusion; 2005 Sep; 45(9):1443-52. PubMed ID: 16131376 [TBL] [Abstract][Full Text] [Related]
6. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Osselaer JC; Cazenave JP; Lambermont M; Garraud O; Hidajat M; Barbolla L; Tardivel R; Defoin L; Waller C; Mendel I; Raidot JP; Kandel G; De Meuter R; Fabrigli P; Dehenau D; Arroyo JL; Padrón F; Gouezec H; Corral M; Jacquet M; Sundin D; Lin L; Corash L Vox Sang; 2008 May; 94(4):315-23. PubMed ID: 18248574 [TBL] [Abstract][Full Text] [Related]
7. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Simonsen AC; Johansson PI; Conlan MG; Jacquet M; Lin JS; Junge K; Lin L; Sørensen H; Borregaard N; Flament J Transfusion; 2006 Mar; 46(3):424-33. PubMed ID: 16533286 [TBL] [Abstract][Full Text] [Related]
8. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Lin L; Conlan MG; Tessman J; Cimino G; Porter S Transfusion; 2005 Oct; 45(10):1610-20. PubMed ID: 16181212 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light. Wagner SJ; Skripchenko A; Myrup A; Awatefe H; Thompson-Montgomery D; Moroff G; Carmichael P; Lin L Transfusion; 2009 Apr; 49(4):704-10. PubMed ID: 19171001 [TBL] [Abstract][Full Text] [Related]
10. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Lozano M; Galan A; Mazzara R; Corash L; Escolar G Transfusion; 2007 Apr; 47(4):666-71. PubMed ID: 17381625 [TBL] [Abstract][Full Text] [Related]
11. Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates. Bruchmüller I; Janetzko K; Bugert P; Mayaudon V; Corash L; Lin L; Klüter H Transfusion; 2005 Sep; 45(9):1464-72. PubMed ID: 16131379 [TBL] [Abstract][Full Text] [Related]
12. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model. Jordan CT; Saakadze N; Newman JL; Lezhava LJ; Maiers TT; Hillyer WM; Roback JD; Hillyer CD Transfusion; 2004 Aug; 44(8):1159-65. PubMed ID: 15265119 [TBL] [Abstract][Full Text] [Related]
13. Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats. Ciaravino V; Hanover J; Lin L; Sullivan T; Corash L Transfusion; 2009 May; 49(5):985-94. PubMed ID: 19175545 [TBL] [Abstract][Full Text] [Related]
14. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528 [TBL] [Abstract][Full Text] [Related]
15. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Lin L; Dikeman R; Molini B; Lukehart SA; Lane R; Dupuis K; Metzel P; Corash L Transfusion; 2004 Oct; 44(10):1496-504. PubMed ID: 15383024 [TBL] [Abstract][Full Text] [Related]
16. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Osselaer JC; Messe N; Hervig T; Bueno J; Castro E; Espinosa A; Accorsi P; Junge K; Jacquet M; Flament J; Corash L Transfusion; 2008 Jun; 48(6):1061-71. PubMed ID: 18346019 [TBL] [Abstract][Full Text] [Related]
17. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Cazenave JP; Waller C; Kientz D; Mendel I; Lin L; Jacquet M; Propst M; Liu W; Corash L; Sundin D; Defoin L; Messe N; Osselaer JC Transfusion; 2010 Jun; 50(6):1210-9. PubMed ID: 20113450 [TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Mintz PD; Neff A; MacKenzie M; Goodnough LT; Hillyer C; Kessler C; McCrae K; Menitove JE; Skikne BS; Damon L; Lopez-Plaza I; Rouault C; Crookston KP; Benjamin RJ; George J; Lin JS; Corash L; Conlan MG Transfusion; 2006 Oct; 46(10):1693-704. PubMed ID: 17002625 [TBL] [Abstract][Full Text] [Related]
19. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Snyder E; Raife T; Lin L; Cimino G; Metzel P; Rheinschmidt M; Baril L; Davis K; Buchholz DH; Corash L; Conlan MG Transfusion; 2004 Dec; 44(12):1732-40. PubMed ID: 15584988 [TBL] [Abstract][Full Text] [Related]
20. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Grellier P; Benach J; Labaied M; Charneau S; Gil H; Monsalve G; Alfonso R; Sawyer L; Lin L; Steiert M; Dupuis K Transfusion; 2008 Aug; 48(8):1676-84. PubMed ID: 18503613 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]